| Literature DB >> 22069742 |
Peter Mantle1, Mirela Modalca, Andrew Nicholls, Calin Tatu, Diana Tatu, Draga Toncheva.
Abstract
(1)H NMR spectroscopy of urine has been applied to exploring metabolomic differences between people diagnosed with Balkan endemic nephropathy (BEN), and treated by haemodialysis, and those without overt renal disease in Romania and Bulgaria. Convenience sampling was made from patients receiving haemodialysis in hospital and healthy controls in their village. Principal component analysis clustered healthy controls from both countries together. Bulgarian BEN patients clustered separately from controls, though in the same space. However, Romanian BEN patients not only also clustered away from controls but also clustered separately from the BEN patients in Bulgaria. Notably, the urinary metabolomic data of two people sampled as Romanian controls clustered within the Romanian BEN group. One of these had been suspected of incipient symptoms of BEN at the time of selection as a 'healthy' control. This implies, at first sight, that metabolomic analysis can be predictive of impending morbidity before conventional criteria can diagnose BEN. Separate clustering of BEN patients from Romania and Bulgaria could indicate difference in aetiology of this particular silent renal atrophy in different geographic foci across the Balkans.Entities:
Keywords: Balkan nephropathy; aristolochic acid; haemodialysis; metabolomics; ochratoxin A; urinalysis
Mesh:
Substances:
Year: 2011 PMID: 22069742 PMCID: PMC3202861 DOI: 10.3390/toxins3070815
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Urinalysis data summarised from detail shown in Tables 1–5 (Supplementary data). Mean values (±SD) for Bulgarian and Romanian control and BEN groups, and a group of non-BEN subjects with urinary tract tumours. Units: creatinine (mmol/L), and other parameters (mmol/mmol creatinine).
| Creatinine | Calcium | Urate | Protein | Sodium | Potassium | Phosphate | Urea | ||
|---|---|---|---|---|---|---|---|---|---|
| Bulgaria | Control | 13.1(7.9) | 0.14(0.1) | 0.25(0.09) | 13.1(7.9) | 18.9(8.3) | 4.9(3.5) | 1.4(0.8) | 23.4(8.7) |
| BEN | 8.8(5.8) | 0.24(0.18) | 0.2(0.18) | 8.8(5.8) | 30.0(15.7) | 6.2(2.0) | 2.6(1.4) | 40.3(11.1) | |
| Romania | Control | 6.4(3.8) | 0.26(0.24) | 0.29(0.14) | 6.4(3.8) | 28.1(13.2) | 5.8(2.6) | 4.3(4.5) | 32.0(12.7) |
| BEN | 4.4(2.5) | 0.14(0.1) | 0.2(0.08) | 4.4(2.5) | 34.6(21.2) | 3.8(1.8) | 1.8(1.4) | 21.2(6.7) | |
| Non-BEN UTT | 11.3(4.2) | 0.37(0.37) | 0.23(0.1) | 11.3(4.2) | 19.2(8.4) | 2.9(0.6) | 2.3(0.9) | 46.1(15.6) |
Figure 1Comparisons of urinary creatinine concentrations in sample groups sourced in Bulgaria and Romania showing dominance of lower values for people diagnosed with BEN. Illustration of Bulgarian data omitted one exceptionally high value (42.5 mmol/L) for a control subject, which otherwise distorts the graphical format. The three lowest values for the Romanian controls were from subjects who had recently been drinking.
Figure 2PLS-DA scores plot of the urinary data from Romanian and Bulgarian BEN patients, familial/regional control subjects and subjects with other forms of kidney disease.
Mean fold change and p values for metabolites identified to change in urine samples from Romanian BEN subjects compared to samples from Romanian Control subjects.
| Metabolite | Mean Fold | Variation | |
|---|---|---|---|
| Protein, amino, organic acids | 1.80 | 4.47 × 10−6 | elevated |
| Lactate | 1.47 | 8.30 × 10−2 | elevated |
| Unknown triplet | 1.57 | 6.61 × 10−4 | elevated |
| Glucose | 1.83 | 1.56 × 10−4 | elevated |
| Myo-inositol | 1.76 | 1.27 × 10−4 | elevated |
| 3-hydroxyisovalerate | 1.39 | 8.88 × 10−4 | reduced |
| Pyruvate | 1.51 | 1.67 × 10−5 | reduced |
| Citrate | 1.93 | 4.38 × 10−4 | reduced |
| Dimethylamine | 1.44 | 7.05 × 10−5 | reduced |
| Trimethylamine | 1.77 | 9.40 × 10−7 | reduced |
| Dimethylglycine | 1.71 | 7.59 × 10−5 | reduced |
| Taurine | 1.46 | 1.31 × 10−3 | reduced |
| Glycine | 1.28 | 2.29 × 10−2 | reduced |
| Creatine | 1.78 | 1.70 × 10−6 | reduced |
| Phosphocreatine | 1.49 | 3.34 × 10−3 | reduced |
| Formate | 2.47 | 1.05 × 10−2 | reduced |
| Trigonelline | 1.99 | 2.49 × 10−4 | reduced |
Mean fold change and p values for metabolites identified to change in urine samples from Bulgarian BEN subjects compared to samples from Bulgarian Control subjects.
| Metabolite | Mean Fold | Variation | |
|---|---|---|---|
| Lactate | 1.43 | 5.93 × 10−3 | elevated |
| Citrulline | 1.49 | 7.36 × 10−3 | elevated |
| Choline | 1.45 | 2.85 × 10−2 | elevated |
| TMAO | 2.29 | 2.89 × 10−4 | elevated |
| Citrate | 0.67 | 1.66 × 10−1 | reduced |
| Succinate | 0.88 | 8.88 × 10−2 | reduced |
| TMA | 1.00 | 3.38 × 10−1 | reduced |
| Glycerophosphocholine | 0.99 | 4.92 × 10−1 | reduced |
Mean fold change and p values for metabolites identified to change in urine samples from Romanian Control subjects compared to samples from Bulgarian Control subjects.
| Metabolite | Mean Fold | Variation | |
|---|---|---|---|
| Citrate | 1.22 | 1.90 × 10−1 | elevated |
| TMA | 1.00 | 2.20 × 10−1 | elevated |
| Glycerophosphocholine | 0.985472668 | 0.454055919 | elevated |
| Phenylacetic acid | 1.41 | 1.96 × 10−2 | elevated |
| Lactate | 1.42 | 4.92 × 10−2 | Reduced |
| Dimethylglycine | 1.692875166 | 0.006970254 | Reduced |
| Choline | 1.537199456 | 0.005899252 | Reduced |
| TMAO | 1.588133198 | 0.009447084 | Reduced |
| Glycine | 1.259082095 | 0.061166452 | Reduced |
| Phosphocreatine | 1.559161391 | 0.003522414 | Reduced |
| Trigonelline | 2.193825386 | 0.001786463 | Reduced |
| Hippurate | 1.53 | 8.45 × 10−2 | Reduced |
Mean fold change and p values for metabolites identified to change in urine samples from Bulgarian BEN subjects compared to samples from Romanian BEN subjects.
| Metabolite | Mean Fold | Variation | |
|---|---|---|---|
| Lactate | 1.52 | 7.27 × 10−3 | Elevated |
| Acetate | 1.36 | 1.36 × 10−1 | Elevated |
| Glucose | 1.70 | 1.49 × 10−4 | Elevated |
| Myo-inositol | 1.23 | 4.80 × 10−3 | Elevated |
| TMAO | 1.28 | 1.68 × 10−1 | Elevated |
| Protein, amino acids and organic acids | 1.86 | 1.50 × 10−6 | elevated |
| Citrate | 1.80 | 5.81 × 10−3 | Reduced |
| Pyruvate | 1.61 | 2.47 × 10−7 | Reduced |
| Taurine | 1.85 | 1.44 × 10−4 | Reduced |
| Glycine | 1.45 | 1.92 × 10−8 | Reduced |
| Phosphocreatine | 1.22 | 8.26 × 10−3 | Reduced |
Figure 4Scores plot of the second and third components with the Romanian BEN samples removed from the visualisation showing the clustering each of the other groups.
Figure 3Scores plot of the first two components showing the separation of the samples from the Romanian BEN subjects compared to all other groups.
Figure 5Scene at rear of house of former BEN patient in Erghevita, Romania showing re-growth of the dominant weed Aristolochia clematitis. May 2004.